TABLE 13: Treatment - teletherapy

% of Cases treated with Teletherapy
Country average (population) Country average (country) England Scotland Northern Ireland Wales
All invasive xnmsc 18.1% 18.4% 18.2% 14.9% 21.5% 19.1%
All xnmsc 0-24 11.9% 11.7% 12.0% 10.8% 14.8% 9.3%
All xnmsc 25-59 21.9% 23.3% 21.8% 20.4% 26.0% 25.1%
All xnmsc 60-79 19.9% 20.1% 20.1% 15.7% 24.0% 20.5%
All xnmsc 80+ 10.3% 9.7% 10.5% 7.5% 10.2% 10.7%
Haematology 8.8% 7.4% 9.0% 8.2% 4.5% 7.9%
Head and Neck 57.3% 55.1% 59.5% 32.8% 61.8% 66.5%
Lower GI 12.5% 12.6% 12.6% 10.2% 14.1% 13.5%
Upper GI 18.2% 17.1% 18.9% 9.9% 15.4% 24.3%
HPB 2.1% 2.2% 2.2% 1.2% 2.2% 3.1%
Trachea, Bronchus & Lung 25.0% 25.6% 25.0% 24.2% 29.0% 24.3%
Melanoma of skin 1.1% 0.8% 1.2% 0.3% 0.9% 0.9%
Breast 32.4% 33.9% 32.2% 32.1% 39.6% 31.8%
Cervix 40.7% 41.2% 40.3% 42.1% 35.6% 46.9%
Other Female Genitals 9.3% 11.6% 8.9% 7.3% 14.0% 16.0%
Prostate 16.2% 14.4% 17.2% 4.1% 22.5% 13.9%
Kidney 5.6% 6.9% 5.4% 6.6% 7.8% 8.0%
Bladder 18.3% 18.6% 18.4% 16.1% 18.3% 21.7%
Brain and CNS 43.8% 41.1% 44.8% 30.9% 42.3% 46.6%
Thyroid & other endocrine glands 7.3% 13.2% 6.5% 1.8% 26.3% 18.2%
CUP 9.0% 10.0% 9.0% 7.5% 14.4% 9.1%
Other invasive cancer 10.8% 11.7% 10.9% 7.8% 17.0% 10.9%
Breast in situ 26.4% 30.2% 25.7% 31.6% 43.8% 19.7%
Cervix in situ 0.0% 0.1% 0.0% 0.0% 0.3% 0.0%
Other tumours 0.8% 0.8% 0.9% 0.1% 1.5% 0.6%
Non-Melanoma Skin Cancer 1.6% 1.3% 1.7% 0.6% 1.5% 1.4%